Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Pneumococcal Vaccine Strategy in CLL
NCT05417165Phase 2Recruiting
- Start
- Sep 2023
- Primary completion
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Prevnar 20, Pneumovax 23 in pneumococcal infection. Started Sep 2023; status: recruiting.
02
Drugs
Prevnar 20Pneumovax 23
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT05417165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417165.